Full video transcriptClick to expand
Auto-generated transcript of @nowyouglow_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00As ampec babies, have you heard of this?
- 0:03Here's two reasons why it could be happening.
- 0:05Number two, you might not expect.
- 0:07The first reason is that these medications work by decreasing absorption.
- 0:11So they delay gastric emptying, which means food doesn't get absorbed as much in your
- 0:16stomach.
- 0:17But along with food, what else isn't getting absorbed in your stomach?
- 0:20Medications.
- 0:21So that means your birth control pills could possibly not be completely absorbed causing
- 0:27you to get pregnant.
- 0:29Number two, a lot of people don't know this, but a lot of people have irregular periods
- 0:34because of obesity, because of an increased BMI.
- 0:37They have irregular periods.
- 0:39That means that they're not ovulating regularly.
- 0:41Once they lose weight, some people will just begin to ovulate regularly because now they
- 0:46have a normal BMI.
- 0:49Ovulating regularly means a regular period, which means getting pregnant in someone who
- 0:54thought that they had infertility.
Ozempic babies explained: what GLP-1s actually do to fertility
Quick answer
GLP-1 receptor agonists like semaglutide delay gastric emptying, which may theoretically affect the absorption timing of oral contraceptives, though total bioavailability reduction has not been confirmed in controlled trials. More robustly supported is the mechanism by which significant weight loss restores ovulatory cycles in people with obesity-related anovulation or PCOS, a recognized clinical phenomenon documented in reproductive endocrinology literature. Patients on GLP-1 therapy who were previously anovulatory should be counseled on the possibility of restored fertility as part of standard care.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Ozempic babies explained: what GLP-1s actually do to fertility, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Ozempic babies explained: what GLP-1s actually do to fertility" from NowYouGlow. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide delay gastric emptying, which may theoretically affect the absorption timing of oral contraceptives, though total bioavailability reduction has not been confirmed in controlled trials.
The reason this review is not generic is the source wording and the canonical claim label "glp1 if you ve heard of ozempic babies here are a couple of reaso." In this clip, the useful excerpt is: "As ampec babies, have you heard of this?" That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
GLP-1 receptor agonists like semaglutide delay gastric emptying, which may theoretically affect the absorption timing of oral contraceptives, though total bioavailability reduction has not been confirmed in controlled trials.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- GLP-1 receptor agonists like semaglutide delay gastric emptying, which may theoretically affect the absorption timing of oral contraceptives, though total bioavailability reduction has not been confirmed in controlled trials. More robustly supported is the mechanism by which significant weight loss restores ovulatory cycles in people with obesity-related anovulation or PCOS, a recognized clinical phenomenon documented in reproductive endocrinology literature. Patients on GLP-1 therapy who were previously anovulatory should be counseled on the possibility of restored fertility as part of standard care.
- GLP-1 drugs do slow gastric emptying, confirmed in trials including Nauck et al. 2023 in Diabetes Care, but this is not their primary mechanism of action.
- Oral contraceptives are absorbed in the small intestine, not the stomach, so the birth control absorption claim as stated is anatomically imprecise.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- GLP-1 drugs do slow gastric emptying, confirmed in trials including Nauck et al. 2023 in Diabetes Care, but this is not their primary mechanism of action.
- Oral contraceptives are absorbed in the small intestine, not the stomach, so the birth control absorption claim as stated is anatomically imprecise.
- No FDA drug interaction warning currently exists between semaglutide or tirzepatide and oral contraceptives, though some clinicians recommend backup contraception out of caution.
- Morley et al. 2022 in Human Reproduction Update found that 5-10% weight loss restored ovulation in a meaningful proportion of women with obesity-related PCOS.
- The WHO estimates PCOS affects 8-13% of reproductive-age women globally, making obesity-related anovulation a common and underrecognized cause of perceived infertility.
- Anyone on a GLP-1 medication with a history of irregular cycles should discuss contraception and fertility changes with a gynecologist or reproductive endocrinologist, not a TikTok comment section.
- Restored ovulation after weight loss is a real clinical event, but it does not confirm full fertility and requires individual medical evaluation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @nowyouglow_ actually say?
The creator offered two explanations for so-called "Ozempic babies." First, that GLP-1 medications "delay gastric emptying," which reduces how well medications, including birth control pills, get absorbed. Second, that obesity causes irregular periods and irregular ovulation, and that weight loss on these drugs can restore regular ovulation in people who assumed they were infertile. Both claims are directionally real, but the details matter a lot here.
She's describing a genuine clinical conversation that has been picking up steam since semaglutide prescriptions exploded. Ob-gyns and endocrinologists have flagged both of these mechanisms in clinical guidance. The question is whether she stated them accurately enough to be useful, or vaguely enough to be dangerous.
Does the science back this up?
Partially, yes. The gastric emptying claim is supported but overstated. The ovulation-restoration claim is well-supported and actually the more clinically significant of the two.
On gastric emptying: GLP-1 receptor agonists do slow gastric motility. A 2023 study by Nauck and colleagues in Diabetes Care confirmed that semaglutide significantly delays gastric emptying, particularly in early treatment weeks. However, the FDA-approved prescribing information for oral contraceptives and the American College of Obstetricians and Gynecologists have not issued a formal warning that GLP-1 drugs render the pill ineffective. The interaction is theoretically plausible but not clinically quantified in large trials.
On ovulation restoration: this is the stronger claim. Polycystic ovary syndrome (PCOS), which affects an estimated 8-13% of reproductive-age women globally per the WHO, is a leading cause of anovulation. Weight loss is a well-documented first-line intervention for restoring ovulatory cycles in people with obesity-related PCOS. A 2022 meta-analysis by Morley and colleagues in Human Reproduction Update found that 5-10% body weight loss restored ovulation in a meaningful proportion of women with PCOS. GLP-1 drugs that produce that weight loss would logically trigger the same effect.
What did they get wrong (or right)?
The creator got the ovulation-restoration mechanism essentially right, and deserves credit for explaining it clearly to a lay audience. The idea that someone "thought that they had infertility" but was actually experiencing obesity-related anovulation is a real clinical scenario, not a fringe theory.
Where she oversimplified: the claim that birth control pills "could possibly not be completely absorbed" because of delayed gastric emptying is not well-supported in the specific way she framed it. Oral contraceptives are absorbed primarily in the small intestine, not the stomach. Slowing gastric emptying delays when the pill reaches the small intestine, but does not necessarily reduce total absorption significantly. The creator conflated "delayed absorption" with "reduced absorption," which are not the same thing. That distinction matters when someone is deciding whether to use backup contraception.
She also used the phrase "these medications work by decreasing absorption," which is inaccurate as a general mechanism. GLP-1 drugs work primarily by stimulating insulin secretion, suppressing glucagon, and reducing appetite, not by blocking absorption the way a drug like orlistat does. That's a meaningful error in a video that's supposed to explain the mechanism.
What should you actually know?
If you're on a GLP-1 medication and using oral contraceptives, talk to your prescriber. Not because this video proved the pill stops working, but because the theoretical interaction is real enough that some clinicians are recommending backup contraception, especially in the first few months of treatment when gastric motility changes are most pronounced.
More importantly, if you have a history of irregular periods tied to a higher BMI, and you're losing significant weight on a GLP-1 drug, your fertility picture may be changing faster than you expect. This is not a reason to panic, but it is a reason to have a conversation with a gynecologist or reproductive endocrinologist. Restored ovulation is not the same as confirmed fertility, and neither is a missed period on GLP-1 therapy necessarily a pregnancy. These drugs also affect cycle regularity through other hormonal pathways that are still being studied.
The "Ozempic baby" framing is catchy but it collapses two separate mechanisms into one vague warning. One of those mechanisms is well-supported. The other is plausible but overstated. A TikTok is not the place to make contraception decisions.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
NowYouGlow · TikTok creator
8.3K views on this video
If you’ve heard of “Ozempic babies” here are a couple of reasons why this might be happening, #2 might surprise you! Comment 👙 to get bikini ready by the summer☀️ #weightloss #weightlosssolution #summerbody #coralgables #glowgang
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about glp-1 drugs do slow gastric emptying, confirmed in trials including?
GLP-1 drugs do slow gastric emptying, confirmed in trials including Nauck et al. 2023 in Diabetes Care, but this is not their primary mechanism of action.
What does the video say about oral contraceptives?
Oral contraceptives are absorbed in the small intestine, not the stomach, so the birth control absorption claim as stated is anatomically imprecise.
What does the video say about no fda drug interaction warning currently exists between semaglutide?
No FDA drug interaction warning currently exists between semaglutide or tirzepatide and oral contraceptives, though some clinicians recommend backup contraception out of caution.
What does the video say about morley et al. 2022 in human reproduction update found?
Morley et al. 2022 in Human Reproduction Update found that 5-10% weight loss restored ovulation in a meaningful proportion of women with obesity-related PCOS.
What does the video say about the who estimates pcos affects 8-13% of reproductive-age women globally,?
The WHO estimates PCOS affects 8-13% of reproductive-age women globally, making obesity-related anovulation a common and underrecognized cause of perceived infertility.
What does the video say about anyone on a glp-1 medication with a history of irregular?
Anyone on a GLP-1 medication with a history of irregular cycles should discuss contraception and fertility changes with a gynecologist or reproductive endocrinologist, not a TikTok comment section.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by NowYouGlow, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.